Adrian Auf Der Maur

USPTO Granted Patents = 17 (Patent Applications = 2)

CIPO Patents = 5

EPO Patents = 8 (Patent Applications = 11)

Average Co-Inventor Count = 4.0

ph-index = 6

Forward Citations = 69(Granted Patents)

Location History:

Zürich, CH (2007)
Ruetihof, CH (2011)
Rütihof, CH (2011 - 2015)
Rutihof, CH (2013 - 2016)
Dietikon, CH (2012 - 2017)
Zurich, CH (2007 - 2020)

Company Filing History:

8 out of 36

Esbatech, an Alcon Biomedical Research Unit LLC

patents

4 out of 5

Delenex Therapeutics Ag

Cell Medica Switzerland Ag

patents

7. 1 out of 1

Esbatech, an Alcon Boimedical Research Unit, LLC

patent

where one patent can have more than one assignee

Years Active: 2007-2020

Loading Chart...

17 patents (USPTO):Sort by Forward CitationsExplore Patents

1. 10570190 - Immunoglobulin frameworks which demonstrate enhanced stability in the intracellular environment and methods of identifying same (2020-02-25),

2. 10125186 - Immunoglobulin frameworks which demonstrate enhanced stability in the intracellular environment and methods of identifying same (2018-11-13),

3. 9683034 - Stable and soluble antibodies inhibiting TNFα (2017-06-20),

4. 9518108 - Immunoglobulin frameworks which demonstrate enhanced stability in the intracellular environment and methods of identifying same (2016-12-13),

5. 9512411 - Nucleic acid encoding antibodies binding to the extracellular domain of the receptor tyrosine kinase ALK (2016-12-06),

6. 9315572 - Stable and soluble antibodies inhibiting TNF alpha (2016-04-19),

7. 9273126 - Humanized antibodies against the beta-amyloid peptide (2016-03-01),

8. 8945563 - Method for treating glioblastoma using antibodies binding to the extracellular domain of the receptor tyrosine kinase ALK (2015-02-03),

9. 8936785 - scFv antibodies which pass epithelial and/or endothelial layers (2015-01-20),

10. 8853362 - Immunoglobulin frameworks which demonstrate enhanced stability in the intracellular environment and methods of identifying same (2014-10-07),

11. 8691228 - Stable and soluble antibodies inhibiting TNFα (2014-04-08),

12. 8389693 - Stable and soluble antibodies inhibiting TNFα (2013-03-05),

13. 8323647 - Humanized antibodies against the β-amyloid peptide (2012-12-04),

14. 8067547 - Stable and soluble antibodies inhibiting TNFα (2011-11-29),

15. 7902340 - Antibodies binding to the extracellular domain of the receptor tyrosine kinase ALK (2011-03-08),

Title: Adrian Auf Der Maur: An Innovator in Antibody Fragment Stability

Introduction

Adrian Auf Der Maur, based in Rutihof, Switzerland, is a prolific inventor with 17 patents to his name. His work primarily focuses on enhancing the stability of single-chain antibody fragments, particularly within intracellular environments. This innovation holds significant implications for the fields of biotechnology and pharmaceuticals.

Latest Patents

Among his latest contributions are patents for immunoglobulin frameworks that exhibit improved stability under intracellular conditions. These compositions serve as frameworks for creating stable and soluble single-chain Fv antibody fragments. The selection of these frameworks is aimed at optimizing intracellular performance, making them ideal for constructing scFv antibody fragments or libraries. This innovation addresses stability and solubility issues that often limit the effectiveness of antibody fragments in the reducing environment of cells. Furthermore, these frameworks can identify conserved residues and consensus sequences that demonstrate enhanced solubility and stability, marking a significant advancement in antibody technology.

Career Highlights

Adrian Auf Der Maur has made significant strides in the field of biomedical research throughout his career. He has worked with notable organizations, such as Esbatech and the Alcon Biomedical Research Unit LLC, where he contributed to groundbreaking research initiatives. His tenure with Delenex Therapeutics AG further showcases his commitment to advancing biopharmaceutical development.

Collaborations

Throughout his career, Auf Der Maur has collaborated with esteemed colleagues, including Alcide Barberis and Stefan Ewert. These partnerships have fostered an environment of innovation and have led to numerous advancements in antibody fragment research.

Conclusion

Adrian Auf Der Maur stands out as a leading innovator in the field of antibody research. His 17 patents reflect his dedication to improving the stability and solubility of single-chain Fv antibody fragments, which are crucial for various applications in biomedicine. As he continues to make impactful contributions, Auf Der Maur's work will undoubtedly pave the way for future advancements in therapeutic applications.

This text is generated by artificial intelligence and may not be accurate.